Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 22c, Beats on Revenue

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.86), $0.22 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $12.07 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Barclays says AI trade is maturing, favors greater diversification
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike